F18.10 is used for uncomplicated inhalant abuse documentation
F18.10 is the ICD-10-CM code for inhalant abuse, uncomplicated. In clinical documentation, this code may appear when a clinician has determined that a client’s inhalant use is clinically relevant and there is no documented intoxication, remission status, or inhalant-induced disorder attached to the diagnosis.
For therapists, counselors, social workers, psychologists, psychiatrists, and other behavioral health professionals, the main documentation task is not simply placing the code in the chart. The note should show the clinical picture behind the diagnosis: the client’s reported use, related impairment, risk factors, treatment focus, interventions used, and response to care.
AutoNotes does not assign diagnoses. Diagnosis selection remains the clinician’s responsibility. AI-assisted documentation can help organize session details into an editable draft, but the provider must review the record, confirm the diagnosis and code, and finalize the note based on clinical judgment.
Clinical context that may support F18.10 documentation
Inhalant use may involve substances such as aerosol sprays, solvents, gases, nitrites, glue, paint thinner, or other products used for psychoactive effects. Documentation should avoid vague language like “substance issue” when the clinical concern is specifically related to inhalants. Clear wording helps connect the diagnosis, treatment plan, and session content.
F18.10 is typically most relevant when the chart reflects inhalant abuse without a separately coded complication. Examples may include a client who reports repeated use of aerosol products at parties, ongoing cravings, conflict with family due to use, missed work or school obligations, or difficulty reducing use despite stated goals.
Progress notes should connect inhalant use to the client’s functioning. Clinicians may document:
- Frequency, pattern, and recent timing of inhalant use
- Triggers, settings, access to substances, and peer or environmental factors
- Impact on mood, relationships, work, school, parenting, or safety
- Client insight, motivation for change, and readiness for treatment
Specific details matter. “Client reported using computer duster twice over the weekend after conflict with partner” is more useful than “Client continues substance use.” The first version gives the treatment team a clearer basis for intervention and follow-up.
F18.10 compared with nearby inhalant-related codes
The F18 code family includes several inhalant-related diagnoses. F18.10 is specific to inhalant abuse without documented complications. If the clinical record supports remission, intoxication, or an inhalant-induced disorder, a different code in the F18 family may be more appropriate. Clinicians should confirm the current ICD-10-CM code set, payer rules, and organizational policies before finalizing the diagnosis.
Common related documentation scenarios include:
- F18.10: Inhalant abuse, uncomplicated
- F18.11: Inhalant abuse, in remission
- F18.12x: Inhalant abuse with intoxication, with the final character depending on the intoxication presentation
- F18.18 or F18.19 code options: Inhalant abuse with other or unspecified inhalant-induced disorder, when supported by the clinical record
The distinction should come from the assessment and documentation, not from convenience. For example, if a client presents during or immediately after inhalant intoxication, the note may need to describe observed symptoms, safety concerns, orientation, risk assessment, and any medical referral. If the client is in remission, the note should support that status with relevant history, time since last use when known, relapse prevention work, and current functioning.
Assessment details to capture before using the code in notes
An intake or diagnostic assessment should include enough detail for another qualified clinician to understand why inhalant abuse is part of the clinical formulation. This does not require excessive narrative. It does require a clear connection between the client’s use pattern, impairment, risk, and treatment need.
Useful assessment content may include the type of inhalant used, age of onset, route and setting of use, recent use history, prior attempts to reduce or stop, withdrawal-like concerns if reported, medical complications, legal or school consequences, and co-occurring symptoms such as anxiety, depression, trauma responses, psychosis, or cognitive concerns.
Safety documentation is especially relevant. Some inhalants can create acute medical risk, impaired judgment, falls, accidents, or dangerous behavior. If safety concerns arise, the record should describe the clinician’s assessment, actions taken, referrals made, and follow-up plan.
Questions that can guide clinical documentation
Clinicians can use structured prompts to gather details without turning the session into an interrogation. The goal is to document clinically meaningful information in the client’s own context.
- “What substances have you been inhaling, and how often has this happened recently?”
- “What tends to happen before and after you use?”
- “How has this affected your health, relationships, work, school, or legal situation?”
- “What has helped you delay, reduce, or avoid use in the past?”
The answers can support both the diagnosis and the treatment plan. They also help the clinician track change over time rather than repeating the same general note each session.
Progress note language for F18.10
A strong progress note for F18.10 should document the session focus, the client’s current symptoms or use pattern, interventions, client response, and plan. SOAP, DAP, BIRP, and GIRP formats can all work if the note shows medical necessity and progress toward treatment goals.
Here is a fictional example using a DAP-style format:
D — Data: Client reported inhaling aerosol spray once since last session after an argument with a sibling. Client described shame, headache afterward, and concern about losing trust with family. Client denied current suicidal ideation and denied current intent to use today. Session focused on triggers, access, and coping options during conflict.
A — Assessment: Client continues to show difficulty interrupting inhalant use when emotionally activated. Insight appears increased, as client identified conflict and isolation as common triggers. Motivation for change is moderate, with stated goal of avoiding use before next session.
P — Plan: Clinician used motivational interviewing and CBT-based trigger mapping. Client agreed to remove access to identified aerosol product, contact a support person after conflict, and practice a 10-minute delay strategy. Continue weekly therapy and review relapse prevention plan next session.
This example does not assume that the code alone explains the clinical need for treatment. The note describes the behavior, impairment, intervention, client response, and next step.
Treatment planning considerations for inhalant abuse
Treatment planning should translate the assessment into measurable goals and clinically appropriate interventions. For inhalant abuse, the plan often includes substance use reduction or abstinence goals, relapse prevention, coping skills, safety planning, and work on co-occurring mental health symptoms.
Goals are easier to track when they are specific. Instead of “Client will stop using inhalants,” a treatment plan might say, “Client will identify three high-risk situations for inhalant use and practice two alternative coping strategies before the next treatment plan review.” This gives the clinician something observable to revisit in progress notes.
Common treatment plan elements may include:
- Problem: Recurrent inhalant use during emotional distress or peer pressure
- Goal: Reduce or discontinue inhalant use and improve safety
- Interventions: Motivational interviewing, CBT skills, relapse prevention, family involvement when appropriate
- Progress measures: Self-reported use, trigger awareness, coping skill use, session attendance, safety incidents
Coordination may also be appropriate. Depending on the client’s presentation, clinicians may consider referral for medical evaluation, psychiatry, substance use treatment, higher level of care, school-based support, or case management. The note should document referrals and the client’s response to them.
Common documentation gaps with F18.10
Many F18.10 notes fall short because they mention the code but do not show the clinical reasoning behind ongoing care. This can make the record harder to follow during supervision, care coordination, audits, or treatment plan reviews.
Watch for these common gaps:
- Documenting “substance use” without naming inhalants or describing the pattern
- Listing the diagnosis without linking it to impairment or treatment goals
- Repeating the same intervention language across sessions without client-specific response
- Omitting safety assessment, medical referral, or access concerns when clinically relevant
Better notes are not always longer. They are more connected. The diagnosis, session content, intervention, and plan should point in the same direction.
How AutoNotes supports editable F18.10 progress note drafts
AutoNotes helps behavioral health clinicians create structured, editable progress note drafts from session details. For inhalant abuse documentation, that can mean a faster starting point for capturing use patterns, triggers, interventions, client response, treatment goals, and next steps.
The clinician stays in control. AutoNotes can help organize information into formats such as SOAP, DAP, BIRP, intake notes, assessments, and treatment plans, but the provider reviews and edits the note before it becomes part of the clinical record. That review is where diagnosis selection, clinical judgment, risk assessment, and payer-specific requirements are confirmed.
For a therapist who sees six or seven clients in a day, the benefit is practical. Instead of writing every F18.10-related note from a blank screen after hours, the clinician can start with a structured draft and refine the clinical details. This can reduce documentation burden while supporting more consistent note structure.
Use F18.10 documentation to support clearer care planning
F18.10 documentation should do more than identify a code. It should help the clinician track the client’s inhalant use, risk, motivation, interventions, and progress toward treatment goals. Clear notes also make it easier to coordinate care and revisit the treatment plan when symptoms, use patterns, or safety needs change.
If documentation is taking too much time after sessions, AutoNotes can help you create editable drafts for progress notes, assessments, and treatment plans while keeping clinical review in your hands. Start your free trial and see how AI-assisted documentation can fit into your existing clinical workflow.
